Boston Scientific Corp.'s Therasphere Y-90 glass microspheres received a PMA for treatment of patients with unresectable hepatocellular carcinoma (HCC). The radioembolization technique has been used in more than 70,000 patients under a humanitarian device exemption over the last 20 years. The U.K.'s NICE also recently recommended Therasphere for treatment of patients with HCC.

Advanced Oncotherapy plc reported new findings demonstrating the potential ability and superiority of its next-generation proton therapy system, LIGHT, to treat resistant cancers. The findings build on research at the Mayo Clinic that highlighted the benefits of combining proton therapy (PT) with targeted small molecule damage repair inhibitors.

Following a missed primary endpoint in its phase III study in treating anti-PD-1-refractory advanced melanoma, Idera Pharmaceuticals Inc. is considering stopping the registrational trial of its synthetic Toll-like receptor 9 (TLR9) agonist or pressing on toward the clinical trial’s second primary endpoint.